Good exposure for Todos: https://insiderfinancial.
Post# of 30066
(Total Views: 849)
Posted On: 03/19/2020 1:49:37 PM
Re: jamesfranklin #28298
Good exposure for Todos: https://insiderfinancial.com/the-race-for-cov...es/179726/
"Before today, the wall street kit maker darling has been AYTU which went up close to 700% after its announcement to distribute the test. AYTU has ordered 100,000 test kits and hopes to be the first to distribute them but competitor TOMDF announced today that it entered into an agreement to distribute the kits and start the 4 week validation process. Their supplier has up to 500,000 test kits ready to ship upon completion of validation in a CLIA lab. Their supplier can manufacture 300,000 daily making TOMDF a major player in the kit space overnight and possibly surpassing AYTU’s stated capacity. It VERY IMPORTANT to not that both are doing rapid tests, but TOMDF has a sensitivity of 98% vs AYTU’s 90%. These are not the nasal swab tests although initially this will be needed to conduct the validation as a comparison. It will be interesting to see how the market reacts to this because TOMDF has a market cap of $8.8 mill versus AYTU’s $33.8 million market cap. If TOMDF has the best of breed test with its 98% sensitivity and can somehow manage an approval it might be able to beat AYTU to the punch line."
"Todos Medical is definitely more of a diagnostics company. They are developing cancer screening tests that are fast, simple, low cost, and are highly accurate using blood. The company has an infrared spectrometer that measures biochemical changes in the blood. The software is able to discriminate between healthy, benign, and cancerous cells. They have two primary cancer tests in the pipeline. Their breast cancer test has a 93% sensitivity and 87% specificity which is quite good when compared to digital mammograms which have a 85% sensitivity and 90% specificity. Their other product is a colon cancer test. The company plans to move beyond cancer into tests for Alzheimer’s Disease and other neurodegenerative disorders. The company is also aligned with Provista Diagnostics which is a privately held company developing blood-based proteomic diagnostics in womens cancer. Provista also has its own Clinical Laboratory Improvement Amendments (CLIA) lab which could be the deciding factor in the approval of the COVID-19 test as they conduct their trial."
"Before today, the wall street kit maker darling has been AYTU which went up close to 700% after its announcement to distribute the test. AYTU has ordered 100,000 test kits and hopes to be the first to distribute them but competitor TOMDF announced today that it entered into an agreement to distribute the kits and start the 4 week validation process. Their supplier has up to 500,000 test kits ready to ship upon completion of validation in a CLIA lab. Their supplier can manufacture 300,000 daily making TOMDF a major player in the kit space overnight and possibly surpassing AYTU’s stated capacity. It VERY IMPORTANT to not that both are doing rapid tests, but TOMDF has a sensitivity of 98% vs AYTU’s 90%. These are not the nasal swab tests although initially this will be needed to conduct the validation as a comparison. It will be interesting to see how the market reacts to this because TOMDF has a market cap of $8.8 mill versus AYTU’s $33.8 million market cap. If TOMDF has the best of breed test with its 98% sensitivity and can somehow manage an approval it might be able to beat AYTU to the punch line."
"Todos Medical is definitely more of a diagnostics company. They are developing cancer screening tests that are fast, simple, low cost, and are highly accurate using blood. The company has an infrared spectrometer that measures biochemical changes in the blood. The software is able to discriminate between healthy, benign, and cancerous cells. They have two primary cancer tests in the pipeline. Their breast cancer test has a 93% sensitivity and 87% specificity which is quite good when compared to digital mammograms which have a 85% sensitivity and 90% specificity. Their other product is a colon cancer test. The company plans to move beyond cancer into tests for Alzheimer’s Disease and other neurodegenerative disorders. The company is also aligned with Provista Diagnostics which is a privately held company developing blood-based proteomic diagnostics in womens cancer. Provista also has its own Clinical Laboratory Improvement Amendments (CLIA) lab which could be the deciding factor in the approval of the COVID-19 test as they conduct their trial."
(2)
(0)